H.C. Wainwright has reiterated its Buy rating on Gain Therapeutics, maintaining a price target of $8.00 per share. The firm’s outlook reflects the biotech’s progress in advancing its lead candidate, GT-02287 (rexaceract), toward Phase 2 clinical trials for Parkinson’s disease.
The U.S. Food and Drug Administration has granted clearance for Gain Therapeutics to proceed with a Phase 2 study of GT-02287, following the completion of Phase 1a and Phase 1b trials in Australia. Those early-stage studies demonstrated target engagement, favorable safety profiles, and tolerability, alongside biomarker and clinical evidence supporting further development. The Phase 2a trial will evaluate oral GT-02287 in both treated and untreated participants with early Parkinson’s disease, with enrollment expected to begin in the third quarter of 2026.
The trial is planned to expand beyond Australian sites to include additional centers in the U.S. and select European locations. H.C. Wainwright noted anecdotal reports from participants in prior studies, including improvements in smell, taste, balance, gait, and sleep. The analyst firm emphasized these signals as potential indicators of therapeutic benefit ahead of the formal trial results.
Gain Therapeutics’ shares, listed on the NASDAQ under GANX, were trading at $1.77 on Wednesday, down 45% year-to-date. The $8 price target implies significant upside potential based on the analyst’s valuation framework. The firm’s rating and target remain unchanged from its prior assessment, underscoring confidence in the candidate’s development trajectory despite the stock’s recent underperformance.
